Blueskytoo
Senior Member (Voting Rights)
Just had this from Cochrane - so the monthly report seems to have gone by the wayside...
How completely, predictably, and despairingly unsurprising….
Just had this from Cochrane - so the monthly report seems to have gone by the wayside...
What the Tamiflu saga tells us about drug trials and big pharma
Today we found out that Tamiflu doesn't work so well after all. Roche, the drug company behind it, withheld vital information on its clinical trials for half a decade, but the Cochrane Collaboration, a global not-for-profit organisation of 14,000 academics, finally obtained all the information. Putting the evidence together, it has found that Tamiflu has little or no impact on complications of flu infection, such as pneumonia.
Or should I say, there has been a "pause" in activity whilst we wait, in limbo, for notification of the next report?Just had this from Cochrane - so the monthly report seems to have gone by the wayside...
View attachment 15012
I hope aligning themselves with NICE means finally withdrawing the current review which still says there is moderate quality evidence that exercise is helpful for CFS.My guess is that Cochrane has decided to find excuses to delay until they know the outcome of the NICE guidelines, then align themselves with them.
PS: and I think the reasoning used is that they want to avoid a situation where they contradict an authority like NICE because that would lead to more bad PR and conflict.
I hope aligning themselves with NICE means finally withdrawing the current review which still says there is moderate quality evidence that exercise is helpful for CFS.
Too late. There are 37Don't count your chickens...
Or should I say, there has been a "pause" in activity whilst we wait, in limbo, for notification of the next report?
I hope aligning themselves with NICE means finally withdrawing the current review which still says there is moderate quality evidence that exercise is helpful for CFS.
How will the new NICE guideline affect Cochrane’s review?
How will the new NICE guideline affect Cochrane’s review?
I think it will have a very big impact on the process of reaching an assessment. The problems with the Larun review were well known but the guideline makes them official in a way that means that to revert to the Larun conclusion would require very clear justification.
It will be an open test of the integrity of the group Bastian has chosen.
Cochrane may retreat using the arguments raised by Busse and Guyatt but if NICE and Cochrane are now supposed to be fused it will all be rather difficult.
How will the new NICE guideline affect Cochrane’s review?